Edotecarin

Cat. No.:	HY-13618
CAS No.:	174402-32-5
Molecular Formula:	$C_{29}H_{28}N_4O_{11}$
Molecular Weight:	608.55
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Edotecarin is a potent inhibitor of topoisomerase I that can induces single-strand DNA cleavage, with IC_{50} of 50 nM.	
IC_{50} & Target	Topoisomerase I 50 nM (IC_{50})	Protein Kinase C 160 μM (IC_{50})
In Vitro	In the presence of human colon cancer cells labeled with ^{3}Hthymidine, edotecarin (0.6 μmol/L) increases the formation of DNA-protein complexes in a time-dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Edotecarin produces an 83% increase in survival in mice bearing intracranial D-456MG glioma and shows a strong antimetastatic effect[1]. Edotecarin results in tumor growth delays ranging from 10.45 days at the lowest dose (3 mg/kg) to 24.83 days at the highest (100 mg/kg). Combination treatment of edotecarin plus irinotecan improves antitumor activity in vivo compared with either agent alone[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Saif MW, et al. Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.

[2]. Ciomei M, et al. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin Cancer Res. 2006 May 1;12(9):2856-61.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA